We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > BGI Genomics

News List

BGI Receives FDA Authorization for Real-Time SARS-CoV-2 Test americanpharmaceuticalreview
April 06, 2020
Gilead Sciences has announced that two Phase III studies to test the safety and efficacy of remdesivir in COVID-19 patients have begun.
BGI Genomics Receives EUA for SARS-CoV-2 Test Kit contractpharma
March 30, 2020
Test can return results within three hours and is intended for the qualitative detection of the virus that causes COVID-19 disease.
BGI Genomics, Pryzm Health to advance precision public health biospectrumasia
May 15, 2019
BGI Genomics and Pryzm will develop foundational capabilities to drive equitable access to precision medicine approaches across the health system.
Natera and BGI Genomics announce $50M partnership biospectrumasia
March 12, 2019
Natera, Inc. , a leader in cell-free DNA genetic testing, and BGI Genomics Co., Ltd., the largest cell-free DNA clinical testing laboratory in China have announced a $50 million partnership to commercialize Natera's Signatera™ MRD test in China, and to d
BGI Genomics Announces Pricing of Initial Public Offering en-cphi.cn
July 17, 2017
BGI Genomics, an independent division of BGI Group, today announced pricing of its initial public offering of 40.1 million shares at a list price of RMB 13.64 per share.